14-day Premium Trial Subscription Sign Up For FreeGet Free

Akebia Therapeutics Stock Forecast NASDAQ:AKBA

Price Target and Analyst Ratings

Most Recent Rating

HC Wainwright is very positive about AKBA and gave it a "Buy" rating on March 15, 2021. The price target was changed from $9.00 to $6.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-03-15 Buy Target Lowered by HC Wainwright $3.60 $9.00 → $6.00
2021-03-15 Overweight Initiated by Cantor Fitzgerald $3.60 $8.00
2021-03-08 Overweight Initiated by Cantor Fitzgerald $3.33 $8.00
2021-03-08 Buy Target Lowered by HC Wainwright $3.33 $9.00 → $6.00
2021-01-29 Neutral - Underweight Downgraded by JPMorgan Chase & Co. $3.24
2020-10-26 Buy Target Lowered by HC Wainwright $2.84 $10.00 → $9.00
2020-09-04 Equal Weight Target Lowered by Morgan Stanley $2.72 $12.00 → $3.00
2020-09-04 Buy Target Lowered by BTIG Research $2.72 $26.00 → $6.00
2020-09-04 Buy Target Lowered by HC Wainwright $2.72 $17.00 → $10.00
2020-09-04 Buy Target Lowered by Mizuho $2.72 $17.00 → $6.00
2020-09-03 Overweight - Neutral Downgraded by JPMorgan Chase & Co. $2.65
2020-08-11 Buy Initiated by Needham & Company LLC $10.28 $18.00
2020-08-11 Buy Reiterated by Mizuho $10.28 $17.00
2020-07-15 Equal Weight Target Raised by Morgan Stanley $12.35 $11.00 → $12.00
2020-07-15 Buy Reiterated by HC Wainwright $12.35
2020-06-29 Buy Initiated by Needham & Company LLC $12.70 $18.00
2020-05-06 Overweight Target Raised by JPMorgan Chase & Co. $11.64 $13.00 → $18.00
2020-05-06 Equal Weight Target Raised by Morgan Stanley $11.64 $9.00 → $11.00
2020-05-06 Positive - Sector Perform Target Raised by Royal Bank of Canada $11.64 $8.00 → $12.00
2020-05-06 Buy Target Raised by HC Wainwright $11.64 $16.00 → $17.00
2020-05-06 Buy Target Raised by Mizuho $11.64 $15.00 → $17.00
2020-05-05 Buy Target Raised by Needham & Company LLC $11.95 $15.00 → $18.00

AKBA Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $2.96 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -26.10% during the next 3 months and, with a 90% probability hold a price between $1.48 and $2.19 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-22 $1.99 $2.46 $2.94
2021-09-23 $1.97 $2.45 $2.92
2021-09-24 $1.95 $2.43 $2.91
2021-09-27 $1.94 $2.41 $2.89
2021-09-28 $1.92 $2.40 $2.87
2021-09-29 $1.90 $2.38 $2.86
2021-09-30 $1.89 $2.36 $2.84
2021-10-01 $1.87 $2.35 $2.82
2021-10-04 $1.85 $2.33 $2.81
2021-10-05 $1.84 $2.31 $2.79
2021-10-06 $1.82 $2.30 $2.78
2021-10-07 $1.80 $2.28 $2.76
2021-10-08 $1.79 $2.26 $2.74
2021-10-11 $1.77 $2.25 $2.73
2021-10-12 $1.75 $2.23 $2.71
2021-10-13 $1.74 $2.21 $2.69
2021-10-14 $1.72 $2.20 $2.68
2021-10-15 $1.70 $2.18 $2.66
2021-10-18 $1.69 $2.16 $2.64
2021-10-19 $1.67 $2.15 $2.63
2021-10-20 $1.65 $2.13 $2.61
2021-10-21 $1.64 $2.11 $2.59
2021-10-22 $1.62 $2.10 $2.58
2021-10-25 $1.60 $2.08 $2.56
2021-10-26 $1.59 $2.07 $2.54
2021-10-27 $1.57 $2.05 $2.53
2021-10-28 $1.55 $2.03 $2.51
2021-10-29 $1.54 $2.02 $2.49
2021-11-01 $1.52 $2.00 $2.48
2021-11-02 $1.50 $1.98 $2.46

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT